Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels


Creative Commons License

SASSİ A., LAZAROSKİ S., WU G., HASLAM S. M. , FLIEGAUF M., MELLOULI F., ...More

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol.133, no.5, pp.1410-1432, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 133 Issue: 5
  • Publication Date: 2014
  • Doi Number: 10.1016/j.jaci.2014.02.025
  • Journal Name: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1410-1432
  • Keywords: Hyper-IgE syndrome, glycosylation, Staphylococcus aureus, signal transducer and activator of transcription 3, dedicator of cytokinesis 8, phosphoglucomutase 3, CONGENITAL DISORDERS, GLYCOSYLATION, DEFICIENCY, MUTASE, DOCK8, IDENTIFICATION, CLONING, DESIGN, PROBES, STAT3
  • Erciyes University Affiliated: Yes

Abstract

Background: Recurrent bacterial and fungal infections, eczema, and increased serum IgE levels characterize patients with the hyper-IgE syndrome (HIES). Known genetic causes for HIES are mutations in signal transducer and activator of transcription 3 (STAT3) and dedicator of cytokinesis 8 (DOCK8), which are involved in signal transduction pathways. However, glycosylation defects have not been described in patients with HIES. One crucial enzyme in the glycosylation pathway is phosphoglucomutase 3 (PGM3), which catalyzes a key step in the synthesis of uridine diphosphate N-acetylglucosamine, which is required for the biosynthesis of N-glycans.